Key result
Morbidly obese patients with end-stage kidney disease achieved similar preoperative weight loss (13.00 kg vs 15.22 kg, p=0.619) and 1-year postoperative weight loss compared to matched non-ESKD patients.
Why the study?
Morbidly obese kidney transplant candidates have limited access to transplantation and higher complication risks, making evaluation of bariatric surgery weight loss in ESKD patients necessary.
Does bariatric surgery result in similar weight loss in morbidly obese patients with ESKD compared to those without ESKD?
Cohort (n=40)
No
Does bariatric surgery result in similar weight loss in morbidly obese patients with ESKD compared to those without ESKD?
Absolute Event Rate: 13% vs 15.22%
p-value: p=0.619
Bariatric surgery is equally effective for weight loss in morbidly obese patients with ESKD compared to those without ESKD, potentially improving their access to kidney transplantation.
May support bariatric surgery consideration in obese ESKD patients; leaves open prospective validation of long-term outcomes.
BACKGROUND: The number of morbidly obese kidney transplant candidates is growing. They have limited access to kidney transplantation and are at a higher risk of postoperative complications. Bariatric surgery is considered as a safe weight loss method in those patients. OBJECTIVES: Matched pair analysis was designed to analyze the preparatory and postoperative weight loss after bariatric procedures in end-stage kidney disease (ESKD) and non-ESKD morbidly obese patients. METHODS: Twenty patients with ESKD underwent bariatric surgery in our Centre of Excellence for Bariatric and Metabolic Surgery between 2015 and 2019 (nine one-anastomosis gastric bypasses, nine Roux-en-Y gastric bypasses, and two sleeve gastrectomies). They were compared with matched pairs from a dataset of 1199 morbidly obese patients without ESKD. Data on demographic factors and comorbidities was recorded. BMI was obtained at the start of the preparatory period preceding the bariatric procedure, at the time of procedure, and during the 1-year follow-up. RESULTS: The ESKD and non-ESKD patients did not differ significantly in preoperative weight loss (13.00 ± 11.69 kg and 15.22 ± 15.96 kg respectively, p = 0.619). During the 1-year follow-up, the weight loss was similar to the non-ESKD group. In the first 3 months, faster weight loss in ESKD was observed. Initial and follow-up BMI values did not differ significantly between groups. We demonstrated that obese patients with ESKD can lose weight as effectively as non-ESKD patients. CONCLUSION: Morbidly obese ESKD patients have an equal weight loss to patients without ESKD. Bariatric surgery could improve access to kidney transplantation and may potentially improve transplantation outcomes of obese patients with ESKD.
No takes yet. Share an insight, caveat, or question.
Dobrzycka et al. (2020) conducted a cohort in Morbid obesity with End-Stage Kidney Disease (ESKD) (n=40). End-stage kidney disease (ESKD) vs. Non-ESKD was evaluated on Preoperative weight loss (kg) (p=0.619). Morbidly obese patients with end-stage kidney disease achieved similar preoperative weight loss (13.00 kg vs 15.22 kg, p=0.619) and 1-year postoperative weight loss compared to matched non-ESKD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: